RxDoctor Payments Data

Lauren Olson, MD

Internal Medicine · San Francisco, CANPI 1639533961

Payments from drug & device makers

$2,395in general payments, 2019–2025

Across 99 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$676
  • AbbVie$425
  • Novo Nordisk$241
  • Boehringer Ingelheim$146
  • Merck$145
  • Pfizer$137
  • plus $624 from 13 others

What the payments were for

  • Food & beverage$2,395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,395 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$59,321
Medicare patients
138
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$55,002
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,778
EliquisApixaban63$45,548
JanuviaSitagliptin Phosphate21$29,526
RybelsusSemaglutide18$26,722
JardianceEmpagliflozin34$26,283
TivicayDolutegravir Sodium12$12,036
TrulicityDulaglutide12$11,750
BelsomraSuvorexant20$11,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,020
DescovyEmtricitabine/Tenofov Alafenam11$9,743
Breo ElliptaFluticasone/Vilanterol17$8,849
Divalproex Sodium12$3,787
Atorvastatin Calcium383$3,538
Levothyroxine Sodium195$2,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$241$81,72569 claims
GileadBiktarvy, Descovy$117$55,52223 claims
PfizerEliquis, Paxlovid$137$46,91592 claims
MerckJanuvia, Belsomra$145$40,66041 claims
Boehringer IngelheimJardiance$146$26,28334 claims
GSKTrelegy Ellipta, Breo Ellipta$37$19,86935 claims
Viiv Healthcare CompanyTivicay$676$12,03612 claims
Lilly USA, LLCTrulicity$112$11,75012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →